In the present study, we present the current knowledge we gathered on distinct functionalities of IRE1α in blood cancer cells and discuss the potential utility of IRE1α inhibitors in the treatment of blood malignancies. This evidence concerns the gene ERN1 and hematopoietic and lymphoid system neoplasm.